Droxinavir
Names | |
---|---|
IUPAC name
3-tert-butyl-1-[(2R,3S)-3-[(2S)-3,3-dimethyl-2-[2-(methylamino)acetamido]butyramido]-2-hydroxy-4-phenylbutyl-1-isopentylurea | |
Other names
SC 55389A | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEMBL | |
ChemSpider | |
PubChem CID |
|
UNII | |
InChI
| |
SMILES
| |
Properties | |
Chemical formula |
C29H51N5O4 |
Molar mass | 533.75 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
(what is ?) | |
Infobox references | |
Droxinavir (also known as SC 55389A) was an experimental protease inhibitor researched by Pharmacia as a treatment for HIV infection. Its research and development was discontinued on March 06, 1995.[1]
References
- ↑ "Drug Profile: Droxinavir". AdisInsight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 23 November 2015.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.